Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | CDK1 | P06493 | 4/20 | 0.53 |
| ▸ | PRUNE1 | Q86TP1 | 1/20 | 0.52 |
| ▸ | CCNE2 | O96020 | 7/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.50 |
| ▸ | CDK2 | P24941 | 7/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 7/20 | 0.49 |
| ▸ | CDK5R1 | Q15078 | 7/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.49 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.49 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.48 |
| ▸ | PDE5A | O76074 | 1/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.48 |
| ▸ | CDK7 | P50613 | 1/20 | 0.48 |
| ▸ | CDK9 | P50750 | 1/20 | 0.48 |
| ▸ | CCNH | P51946 | 1/20 | 0.48 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7971734 | 0.82 | PRUNE1 (0.60) | TDP1CDK1PRUNE1CCNE2CCNE1 | |
| SCHEMBL7960337 | 0.81 | PRUNE1 (0.59) | TDP1CDK1PRUNE1CCNE2CCNE1 | |
| SCHEMBL3682525 | 0.77 | PRUNE1 (0.67) | TDP1CDK1PRUNE1CCNE2CCNE1 | |
| SCHEMBL15619030 | 0.73 | CCNE2 (0.68) | TDP1CDK1PRUNE1CCNE2CCNE1 | |
| SCHEMBL15618715 | 0.72 | CDK2 (0.71) | TDP1CDK1PRUNE1CCNE2CCNE1 | |
| SCHEMBL1394954 | 0.70 | CCNE1 (0.77) | TDP1CDK1CCNE2CCNE1CDK2 | |
| Myoseverin SCHEMBL13325947 | 0.70 | TDP1 (1.00) | TDP1CDK1CCNE2CCNE1CDK2 | |
| Myoseverin SCHEMBL29376276 | 0.70 | TDP1 (1.00) | TDP1CDK1CCNE2CCNE1CDK2 | |
| SCHEMBL1496625 | 0.69 | LMNA (0.67) | — | |
| SCHEMBL7960318 | 0.69 | TP53 (0.46) | CDK1PRUNE1CCNE2CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6297250-B1 | USEFUL FOR INHIBITING TRANSPORT OF NUCLEOSIDES OR PURINES ACROSS CELL MEMBRANES, THEREBY TO POTENTIATE THE ACTIVITY OF VARIOUS CYTOTOXIC ANTITUMOR DRUGS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 2001-10-02 | — | — | US | claimed |
| US-20240166770-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF CELL-PENETRATING ANTIBODIES | YALE UNIVERSITY | 2024-05-23 | — | — | US | disclosed |
| WO-2021077070-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF CELL-PENETRATING ANTIBODIES | YALE UNIVERSITY (US) | 2021-04-22 | — | — | WO | disclosed |
| US-6297250-B1 | USEFUL FOR INHIBITING TRANSPORT OF NUCLEOSIDES OR PURINES ACROSS CELL MEMBRANES, THEREBY TO POTENTIATE THE ACTIVITY OF VARIOUS CYTOTOXIC ANTITUMOR DRUGS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 2001-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166770-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF CELL-PENETRATING ANTIBODIES | SLC29A1, SLC29A2, SLC7A1 | TDP1 636/4885CDK1 3685/4885PRUNE1 3761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.